Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14659599 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL20281001 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL6473099 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL3276506 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL16431695 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL17866955 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL9985445 | 1.00 | AKR1B1 (0.35) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL2338047 | 0.93 | AKR1B1 (0.36) | AKR1B1MPITHRB | |
| SCHEMBL448041 | 0.93 | AKR1B1 (0.36) | AKR1B1MPITHRB | |
| SCHEMBL7153437 | 0.93 | AKR1B1 (0.36) | AKR1B1MPITHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-10765627-B2 | Immunogenic composition against Campylobacter jejuni | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190336440-A1 | Immunogenic Composition Against Campylobacter Jejuni | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2019-11-07 | — | — | US | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10363213-B2 | Immunogenic composition against Campylobacter jejuni | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180320170-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2018-11-08 | — | — | US | disclosed |
| US-20180271778-A1 | Immunogenic Composition Against Campylobacter Jejuni | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2018-09-27 | — | — | US | disclosed |
| US-9999591-B2 | Immunogenic composition against Campylobacter jejuni | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2018-06-19 | — | — | US | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| EP-2185189-B1 | CAPSULE COMPOSITION FOR USE AS IMMUNOGEN AGAINST CAMPYLOBACTER JEJUNI | US NAVY (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
| EP-1933865-B1 | IMMUNOGENIC CAPSULE COMPOSITION FOR USE AS A VACCINE COMPONENT AGAINST CAMPYLOBACTER JEJUNI | US NAVY (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20150273037-A1 | Immunogenic composition against Campylobacter jejuni | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2015-10-01 | — | — | US | disclosed |
| US-9084809-B2 | Immunogenic capsule composition for use as a vaccine component against Campylobacter jejuni | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-07-21 | — | — | US | disclosed |
| EP-2786763-A1 | Capsule composition for use as immunogen against Campylobacter jejuni | The United States of America as Represented by The Secretary of the Navy (US) | 2014-10-08 | — | — | EP | disclosed |
| US-7700578-B2 | Capsule composition for use as immunogen against Campylobacter jejuni | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090004223-A1 | Capsule composition for use as immunogen against campylobacter jejuni | UNITED STATES OF AMERICA AS REPRESENTED BY THE SEC. OF THE NAVY | 2009-01-01 | — | — | US | disclosed |
| US-20070065461-A1 | Immunogenic capsule composition for use as a vaccine component against campylobacter jejuni | UNIVERSITY OF GUELPH (CA) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004223-A1 | Capsule composition for use as immunogen against campylobacter jejuni | ST3GAL3, DDOST, CAPG | AKR1B1 4451/4885MPI 291/4885LMNA 4534/4885 |
| US-10765627-B2 | Immunogenic composition against Campylobacter jejuni | TLR6, TLR2, SIGLEC9 | AKR1B1 3981/4885MPI 208/4885LMNA 3469/4885 |
| US-20070065461-A1 | Immunogenic capsule composition for use as a vaccine component against campylobacter jejuni | TLR5, GNE, NOD2 | AKR1B1 4761/4885MPI 2494/4885LMNA 1731/4885 |
| US-20190336440-A1 | Immunogenic Composition Against Campylobacter Jejuni | TLR6, TLR2, SIGLEC9 | AKR1B1 3981/4885MPI 208/4885LMNA 3469/4885 |
| US-20150273037-A1 | Immunogenic composition against Campylobacter jejuni | TLR6, TLR2, TLR9 | AKR1B1 3982/4885MPI 221/4885LMNA 3446/4885 |
| US-20180271778-A1 | Immunogenic Composition Against Campylobacter Jejuni | TLR6, TLR2, SIGLEC9 | AKR1B1 3981/4885MPI 208/4885LMNA 3469/4885 |
| US-10363213-B2 | Immunogenic composition against Campylobacter jejuni | TLR6, TLR2, SIGLEC9 | AKR1B1 3981/4885MPI 208/4885LMNA 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.